Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
Advertisement

Related Content

Asia Spotlight: Merck In Multiple Partnerships To Finance Hep C Treatment In India
Exclusive: Merck In Multiple Partnerships To Finance Hep C Treatment In India
A Closer Look At Merck's Commercial Restructuring: What Happened To India?
Violation Of Januvia Patents Is Different From Other Cases, Says Merck India Head
Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?
Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share
Novartis Aims Double Edged Attack With Galvus And Jalra To Take On Merck's Januvia In India
Advertisement
UsernamePublicRestriction

Register

SC077757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel